Rocket Lab Delays Neutron Launch as Vanda Trial Misses Target

The volatility extended to the pharmaceutical sector, where Vanda Pharmaceuticals saw its stock retreat 6% to $3.95. This decline followed the announcement that the company’s Phase 3 clinical trial for a social-anxiety treatment failed to achieve its primary endpoint, casting doubt on the candidate's immediate commercial path.

Contrasting the broader downward trend, Netcapital shares surged 36% to $2.16. The rally arrived after the firm confirmed it had successfully regained compliance with the Nasdaq’s minimum bid price requirement, effectively resolving the threat of delisting that had previously weighed on its market performance.